

1645  
IPAC

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))		Docket No. 20155
---	--	---------------------

In Re Application Of: Axel Kallies, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/589,321	August 14, 2006	Unassigned	23389	Unassigned	Unassigned

Title:

**MODIFIED CELLS AND METHODS OF USING SAME**

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
  - the statement specified in 37 CFR 1.97(e);


**OR**

- the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
 20155

In Re Application of: Axel Kallies, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/589,321	August 14, 2006	Unassigned	23389	Unassigned	Unassigned

Title:

**MODIFIED CELLS AND METHODS OF USING SAME**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \_\_\_\_\_ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
  - Charge the amount of \_\_\_\_\_
  - Credit any overpayment.
  - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

October 24, 2006


(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
 Signature

Dated: October 24, 2006

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
 400 Garden City Plaza, Suite 300  
 Garden City, New York 11530  
 516-742-4343

CC:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Axel Kallies, et al.      **Examiner:** Unassigned  
**Serial No.:** 10/589,321      **Art Unit:** Unassigned  
**Filed:** August 14, 2006      **Docket:** 20155  
**For:** MODIFIED CELLS AND METHODS  
OF USING SAME      **Dated:** October 24, 2006

Mail Stop PCT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Kallies A. et al., "Plasma Cell Ontogeny Defined by Quantitative Changes in Blimp-1 Expression", *Journal of Experimental Medicine* 200(8):967-977 (2004);
2. Knödel M. et al., "Reversal of Blimp-1-Mediated Apoptosis by A1, a Member of the Bcl-2 Family", *European Journal of Immunology* 29:2988-2998 (1999);
3. Baxendale S. et al., "The B-Cell Maturation Factor Blimp-1 Specifies Vertebrate Slow-Twitch Muscle Fiber Identity in Response to Hedgehog Signaling", *Nature Genetics* 36(1):88-93 (2004);

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 24, 2006



Xiaochun Zhu

4. Tunyaplin C. et al., "Characterization of the B Lymphocyte-Induced Maturation Protein-1 (Blimp-1) Gene, mRNA Isoforms and Basal Promoter", *Nucleic Acids Research* 28(24):4846-4855 (2000);
5. Reljic R. et al., "Suppression of Signal Transducer and Activator of Transcription 3-Dependent B Lymphocyte Terminal Differentiation by BCL-6", *Journal of Experimental Medicine* 192(12):1841-1847 (2000);
6. Chang D.H. et al., "BLIMP-I: Trigger for Differentiation of Myeloid Image", *Nature Immunology* 1(2):169-176 (2000); and
7. Angelin-Duclos C. et al., "Role of B-Lymphocyte-Induced Maturation Protein-1 in Terminal Differentiation of B Cells and Other Cell Lineages", *Cold Spring Harbor Symposia on Quantitative Biology* 64:61-70 (1999).

The references were cited in an International Search Report dated April 13, 2005 received from the Australian Patent Office. Applicants are submitting a copy of the above-cited references. Applicants previously submitted a copy of the International Search Report on August 14, 2006. The relevance of the above-identified references has been described in the International Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.


Respectfully submitted,



Xiaochun Zhu  
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

XZ:dg

Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional)		Application Number				
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>		20155		10/589,321				
<i>(Use several sheets if necessary)</i>								
								
		Applicant(s)						
		Axel Kallies, et al.						
		Filing Date		Group Art Unit				
		August 14, 2006		Unassigned				
<b>FOREIGN PATENT DOCUMENTS</b>								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		Kallies A. et al., "Plasma Cell Ontogeny Defined by Quantitative Changes in Blimp-1 Expression", <i>Journal of Experimental Medicine</i> 200(8):967-977 (2004)						
		Knödel M. et al., "Reversal of Blimp-1-Mediated Apoptosis by A1, a Member of the Bcl-2 Family", <i>European Journal of Immunology</i> 29:2988-2998 (1999)						
		Baxendale S. et al., "The B-Cell Maturation Factor Blimp-1 Specifies Vertebrate Slow-Twitch Muscle Fiber Identity in Response to Hedgehog Signaling", <i>Nature Genetics</i> 36(1):88-93 (2004)						
		Tunyaplin C. et al., "Characterization of the B Lymphocyte-Induced Maturation Protein-1 (Blimp-1) Gene, mRNA Isoforms and Basal Promoter", <i>Nucleic Acids Research</i> 28(24):4846-4855 (2000)						
		Reljic R. et al., "Suppression of Signal Transducer and Activator of Transcription 3-Dependent B Lymphocyte Terminal Differentiation by BCL-6", <i>Journal of Experimental Medicine</i> 192(12):1841-1847 (2000)						
		Chang D.H. et al., "BLIMP-1: Trigger for Differentiation of Myeloid Image", <i>Nature Immunology</i> 1(2):169-176 (2000)						
EXAMINER		DATE CONSIDERED						
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								